放射配体治疗市场报告：2030 年趋势、预测与竞争分析

放射配体治疗的趋势和预测

预计到 2030 年，全球放射配体治疗市场将达到约 138 亿美元，2024 年至 2030 年的复合年增长率为 5.0%。该市场的主要驱动因素是癌症发病率的上升和对有效治疗的高需求。全球放射配体治疗市场的未来看起来充满希望，医院、诊所和诊断中心市场充满机会。

放射配体治疗市场洞察

Lucintel 预测，由于癌症诊断的高需求，氟 18 在整个预测期内仍将是最大的细分市场。

由于久坐生活方式的普及和全球癌症病例的不断增加，医院将继续成为该市场的最大细分市场。

由于专门的癌症医院和研究中心的存在以及全部区域的癌症发病率增加，北美在预测期内可能仍然是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球放射配体治疗市场预计将达到 138 亿美元。

Q2.市场成长预测是多少：

A2. 2024年至2030年，全球放射配体治疗市场预计将以5.0%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动因素是癌症发生率的上升和对有效治疗的高需求。

Q4.市场的主要细分市场是：

A4. 放射配体治疗市场的未来前景广阔，医院、诊所和诊断中心市场充满机会。

Q5.市场的主要企业是：

A5. 主要的放射配体治疗公司是：

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，由于癌症诊断的高需求，氟 18 在整个预测期内仍将是其最大的细分市场。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于专门的癌症医院和研究中心的存在以及全部区域癌症发病率的增加，预计北美在预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球放射配体治疗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球放射配体治疗市场趋势（2018-2023）与预测（2024-2030）
• 按同位素分類的全球放射配体治疗市场
  • 氟18
  • 镓68
  • 镏-177
  • 其他的
• 按目标受体分類的全球放射配体治疗市场
  • 摄护腺特异性膜抗原
  • 生长抑制素受体
  • 表皮生长因子受体
  • 其他的
• 按适应症分類的全球放射配体治疗市场
  • 摄护腺癌
  • 神经内分泌肿瘤
  • 乳癌
  • 其他的
• 按最终用途分類的全球放射配体治疗市场
  • 医院和诊所
  • 诊断中心
  • 其他的

第四章 2018-2030年区域市场趋势及预测分析

• 全球放射配体治疗市场按地区划分
• 北美放射配体治疗市场
• 欧洲放射配体治疗市场
• 亚太地区放射配体治疗市场
• 其他地区放射配体治疗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按同位素分類的全球放射配体治疗市场成长机会
  • 按目标受体分類的全球放射配体治疗市场成长机会
  • 全球放射配体治疗市场成长机会（按适应症）
  • 全球放射配体治疗市场成长机会（依最终用途）
  • 按地区分類的全球放射配体治疗市场成长机会
• 全球放射配体治疗市场的新兴趋势
• 战略分析
  • 新产品开发
  • 全球放射配体治疗市场的产能扩张
  • 全球放射配体治疗市场的合併、收购与合资企业
  • 认证和许可

第七章主要企业概况

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy Trends and Forecast

The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and high demand for effective treatment.

A more than 150-page report is developed to help in your business decisions.

Radioligand Therapy by Segment

The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.

Radioligand Therapy Market by Isotope [Shipment Analysis by Value from 2018 to 2030]:

• Fluorine - 18
• Gallium - 68
• Lutetium - 177
• Others

Radioligand Therapy Market by Targeted Receptor [Shipment Analysis by Value from 2018 to 2030]:

• Prostate-Specific Membrane Antigen
• Somatostatin Receptor
• Epidermal Growth Factor Receptor
• Others

Radioligand Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

• Prostate Cancer
• Neuroendocrine Tumors
• Breast Cancer
• Others

Radioligand Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Diagnostic Centers
• Others

Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Radioligand Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy Market Insights

Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.

Within this market, hospitals will remain the largest segment due to increasing prevalence of a sedentary way of living and growing cases of cancer across the globe.

North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.

Features of the Global Radioligand Therapy Market

Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).

Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the radioligand therapy market size?

Answer: The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030.

Q2. What is the growth forecast for radioligand therapy market?

Answer: The global radioligand therapy market is expected to grow with a CAGR of 5.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the radioligand therapy market?

Answer: The major drivers for this market are rising cancer rates and high demand for effective treatment.

Q4. What are the major segments for radioligand therapy market?

Answer: The future of the radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets.

Q5. Who are the key radioligand therapy market companies?

Answer: Some of the key radioligand therapy companies are as follows:

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Q6. Which radioligand therapy market segment will be the largest in future?

Answer: Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.

Q7. In radioligand therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radioligand therapy market by isotope (fluorine - 18, gallium - 68, lutetium - 177, and others), targeted receptor (prostate-specific membrane antigen, somatostatin receptor, epidermal growth factor receptor, and others), indication (prostate cancer, neuroendocrine tumors, breast cancer, and others), end use (hospitals & clinics, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radioligand Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radioligand Therapy Market by Isotope
  • 3.3.1: Fluorine - 18
  • 3.3.2: Gallium - 68
  • 3.3.3: Lutetium - 177
  • 3.3.4: Others
• 3.4: Global Radioligand Therapy Market by Targeted Receptor
  • 3.4.1: Prostate-specific Membrane Antigen
  • 3.4.2: Somatostatin Receptor
  • 3.4.3: Epidermal Growth Factor Receptor
  • 3.4.4: Others
• 3.5: Global Radioligand Therapy Market by Indication
  • 3.5.1: Prostate Cancer
  • 3.5.2: Neuroendocrine Tumors
  • 3.5.3: Breast Cancer
  • 3.5.4: Others
• 3.6: Global Radioligand Therapy Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Diagnostic Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radioligand Therapy Market by Region
• 4.2: North American Radioligand Therapy Market
  • 4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.3: European Radioligand Therapy Market
  • 4.3.1: European Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.4: APAC Radioligand Therapy Market
  • 4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.5: ROW Radioligand Therapy Market
  • 4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
  • 6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
  • 6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
  • 6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
  • 6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
• 6.2: Emerging Trends in the Global Radioligand Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: POINT Biopharma Global
• 7.3: Molecular Partners
• 7.4: Telix Pharmaceuticals
• 7.5: Fusion Pharma
• 7.6: Lantheus Holdings
• 7.7: Curium
• 7.8: Precrix
• 7.9: Orano
• 7.10: Artios Pharma